Key result
Reldesemtiv, a second-generation fast skeletal muscle troponin activator, demonstrated increased muscle force generation in a phase 1 clinical trial.
The discovery of reldesemtiv provides a potent fast skeletal muscle troponin activator that increases muscle force generation, with potential applications in amyotrophic lateral sclerosis.
Hypothesis-generating for ALS; extends troponin activation data but requires clinical validation.
High Resolution Image Download MS PowerPoint Slide The discovery of reldesemtiv, a second-generation fast skeletal muscle troponin activator (FSTA) that increases force production at submaximal stimulation frequencies, is reported. Property-based optimization of high throughput screening hit 1 led to compounds with improved free exposure and in vivo muscle activation potency compared to the first-generation FSTA, tirasemtiv. Reldesemtiv demonstrated increased muscle force generation in a phase 1 clinical trial and is currently being evaluated in clinical trials for the treatment of amyotrophic lateral sclerosis.
No takes yet. Share an insight, caveat, or question.
Collibee et al. (2021) studied Impaired Muscle Function / Amyotrophic Lateral Sclerosis. Reldesemtiv was evaluated on Muscle force generation. Reldesemtiv, a second-generation fast skeletal muscle troponin activator, demonstrated increased muscle force generation in a phase 1 clinical trial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: